Tromp J, Ferreira JP, Janwanishstaporn S, et al. Heart failure around the world. Eur J Heart Fail. 2019;21(10):1187–96.

Article  PubMed  Google Scholar 

Heidenreich PA, Bozkurt B, Aguilar D et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e876-e894.

Rubio-Gracia J, Demissei BG, Ter Maaten JM, et al. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. Int J Cardiol. 2018;258:185–91.

Article  PubMed  Google Scholar 

Carvalho PEP, Veiga TMA, Simões E, Silva AC, et al. Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials. Clin Res Cardiol. 2023;112(8):1044–55.

Article  CAS  PubMed  Google Scholar 

Au AG, McAlister FA, Bakal JA, et al. Predicting the risk of unplanned readmission or death within 30 days of discharge after a heart failure hospitalization. Am Heart J. 2012;164(3):365–72.

Article  PubMed  Google Scholar 

Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997;157(1):99–104.

Article  CAS  PubMed  Google Scholar 

Kimmoun A, Takagi K, Gall E, et al. Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta-regression in the past four decades. Eur J Heart Fail. 2021;23(3):420–31.

Article  CAS  PubMed  Google Scholar 

Wang Z, Dong Y, Gao Q, et al. The role of acute heart failure index (AHFI) combined with emergency heart failure mortality risk grade (EHMRG) in the evaluation of clinical outcomes and prognosis in patients with acute heart failure. Acta Cardiol. 2022;77(6):488–93.

Article  CAS  PubMed  Google Scholar 

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.

Article  CAS  PubMed  Google Scholar 

Chan WB. Clinical use of sodium-glucose co-transporter-2 inhibitors in Chinese patients with type 2 diabetes mellitus. Singap Med J. 2019;60(6):309–13.

Article  Google Scholar 

Lee CH, Wu MZ, Lui DT, et al. Comparison of serum ketone levels and cardiometabolic efficacy of Dapagliflozin versus Sitagliptin among insulin-treated Chinese patients with type 2 diabetes Mellitus. Diabetes Metab J. 2022;46(6):843–54.

Article  PubMed  PubMed Central  Google Scholar 

Ji L, Lu Y, Li Q, et al. Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: a phase III, randomized, double-blind, placebo-controlled, parallel study. Diabetes Obes Metab. 2023;25(7):1839–48.

Article  CAS  PubMed  Google Scholar 

Lv J, Guo L, Wang R, Chen J. Efficacy and safety of sodium-glucose Cotransporter-2 inhibitors in nondiabetic patients with chronic kidney disease: a review of recent evidence. Kidney Dis (Basel). 2023;9(5):326–41.

Article  PubMed  Google Scholar 

Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954–60.

Article  PubMed  PubMed Central  Google Scholar 

Lytvyn Y, Bjornstad P, Udell JA, et al. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017;136(17):1643–58.

Article  CAS  PubMed  Google Scholar 

Wiviott SD, Raz I, Bonaca MP, et al. The design and rationale for the dapagliflozin effect on cardiovascular events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018;200:83–9.

Article  CAS  PubMed  Google Scholar 

Kosiborod MN, Jhund PS, Docherty KF, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation. 2020;141(2):90–9.

Article  CAS  PubMed  Google Scholar 

Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22(4):713–22.

Article  CAS  PubMed  Google Scholar 

Ibrahim A, Ghaleb R, Mansour H, et al. Safety and efficacy of adding dapagliflozin to furosemide in type 2 diabetic patients with decompensated heart failure and reduced ejection fraction. Front Cardiovasc Med. 2020;7:602251.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627–39.

Article  CAS  PubMed  Google Scholar 

Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion - a position statement from the heart failure association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(2):137–55.

Article  PubMed  Google Scholar 

Mori T, Yano T, Yoshioka K, et al. Pre-stroke loop diuretics and anemia in elderly patients are associated factors of severe renal dysfunction at the time of acute stroke onset. J Cardiovasc Dev Dis. 2023;10(9):405.

PubMed  PubMed Central  Google Scholar 

Schechter M, Wiviott SD, Raz I, et al. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. Lancet Diabetes Endocrinol. 2023;11(4):233–41.

Article  CAS  PubMed  Google Scholar 

Charaya K, Shchekochikhin D, Andreev D, et al. Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study. Open Heart. 2022;9(1):e001936.

Article  PubMed  PubMed Central  Google Scholar 

Kambara T, Shibata R, Osanai H, et al. Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure. Ther Adv Cardiovasc Dis. 2019;13:1753944719894509.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yeoh SE, Osmanska J, Petrie MC, et al. Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics. Eur Heart J. 2023;44(31):2966–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Charaya K, Shchekochikhin D, Agadzhanyan A, et al. Impact of dapagliflozin treatment on serum sodium concentrations in acute heart failure. Cardiorenal Med. 2023;13(1):101–8.

Article  CAS  PubMed  Google Scholar 

Hommers L, Scherf-Clavel M, Stempel R, et al. Antipsychotics in routine treatment are minor contributors to QT prolongation compared to genetics and age. J Psychopharmacol. 2021;35(9):1127–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mourad A, Stiber JA, Perfect JR, et al. Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone. J Antimicrob Chemother. 2019;74(1):228–33.

CAS  PubMed  Google Scholar 

Funahashi Y, Chowdhury S, Eiwaz MB, et al. Acute cardiorenal syndrome: models and heart-kidney connectors. Nephron. 2020;144(12):629–33.

Article  PubMed  Google Scholar 

Testani JM, Damman K. Venous congestion and renal function in heart failure it’s complicated. Eur J Heart Fail. 2013;15(6):599–601.

Article  PubMed  Google Scholar 

Gessner A, Gemeinhardt A, Bosch A, et al. Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. Cardiovasc Diabetol. 2022;21(1):4.

Article  CAS